{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:10:13Z","timestamp":1790403013474,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"DOI":"10.7759\/cureus.92149","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:27:11Z","timestamp":1757690831000},"source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mayuri","family":"Quishpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Endara-Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselyn","family":"Caizapanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisson","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayana","family":"Tenesaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Asto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odalis","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelya","family":"Rengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesis","family":"Vaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Sarmiento-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910554","article-title":"Endometriosis: epidemiology, classification, pathogenesis, treatment and genetics (review of literature)","volume":"22","author":"Smolarz B","year":"2021","unstructured":"Smolarz B, Szy\u0142\u0142o K, Romanowicz H. Endometriosis: epidemiology, classification, pathogenesis, treatment and genetics (review of literature). Int J Mol Sci. 2021, 22:10554. 10.3390\/ijms221910554","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP\/04-23-6805","article-title":"Endometriosis: a review of recent evidence and guidelines","volume":"53","author":"Crump J","year":"2024","unstructured":"Crump J, Suker A, White L. Endometriosis: a review of recent evidence and guidelines. Aust J Gen Pract. 2024, 53:11-8. 10.31128\/AJGP\/04-23-6805","journal-title":"Aust J Gen Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2025.104830","article-title":"Twenty-five years of research in endometriosis","volume":"50","author":"Garcia-Velasco JA","year":"2025","unstructured":"Garcia-Velasco JA, Vigan\u00f2 P, Somigliana E. Twenty-five years of research in endometriosis. Reprod Biomed Online. 2025, 50:104830. 10.1016\/j.rbmo.2025.104830","journal-title":"Reprod Biomed Online"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.51288\/00840311","article-title":"Epidemiology, clinic and evolution in patients with endometriosis (Article in Spanish)","volume":"84","author":"Molina Rodr\u00edguez R","year":"2024","unstructured":"Molina Rodr\u00edguez R. Epidemiology, clinic and evolution in patients with endometriosis (Article in Spanish). Rev Obstet Ginecol Venez. 2024, 84:299-306. 10.51288\/00840311","journal-title":"Rev Obstet Ginecol Venez"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2020.07.011","article-title":"The prevalence of endometriosis in adolescents with pelvic pain: a systematic review","volume":"33","author":"Hirsch M","year":"2020","unstructured":"Hirsch M, Dhillon-Smith R, Cutner AS, Yap M, Creighton SM. The prevalence of endometriosis in adolescents with pelvic pain: a systematic review. J Pediatr Adolesc Gynecol. 2020, 33:623-30. 10.1016\/j.jpag.2020.07.011","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"ref6","unstructured":"Endometriosis. (2025). Accessed. July 5, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/endometriosis."},{"key":"ref7","article-title":"Living With Endometriosis in Ecuador (Book in Spanish)","author":"Castro Velarde AJ","year":"2020","unstructured":"Castro Velarde AJ. Living With Endometriosis in Ecuador (Book in Spanish). Universidad de las Am\u00e9ricas, Quito, Ecuador; 2020."},{"key":"ref8","article-title":"Endometriosis: a challenge in gynecology and obstetrics. Case report (Article in Spanish)","volume":"24","author":"Le\u00f3n MF","year":"2022","unstructured":"Le\u00f3n MF, Mac\u00edas JM, Varela EJ, Castillo DX, Loaiza YA. Endometriosis: a challenge in gynecology and obstetrics. Case report (Article in Spanish). Ateneo. 2022, 24:68-78.","journal-title":"Ateneo"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis","volume":"382","author":"Zondervan KT","year":"2020","unstructured":"Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020, 382:1244-56. 10.1056\/NEJMra1810764","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i1.17","article-title":"Endometriosis in an indigenous African women population","volume":"22","author":"Ohayi S","year":"2022","unstructured":"Ohayi S, Onyishi N, Mbah S. Endometriosis in an indigenous African women population. Afr Health Sci. 2022, 22:133-8. 10.4314\/ahs.v22i1.17","journal-title":"Afr Health Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000719","article-title":"Racial and ethnic disparities in access to minimally invasive gynecologic surgery for benign pathology","volume":"33","author":"Barnes WA","year":"2021","unstructured":"Barnes WA, Carter-Brooks CM, Wu CZ, Acosta DA, Vargas MV. Racial and ethnic disparities in access to minimally invasive gynecologic surgery for benign pathology. Curr Opin Obstet Gynecol. 2021, 33:279-87. 10.1097\/GCO.0000000000000719","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gine.2021.100686","article-title":"Endometriosis. A life-long journey (Article in Spanish)","volume":"48","author":"Carrillo Torres P","year":"2021","unstructured":"Carrillo Torres P, Mart\u00ednez Zamora MA, Carmona Herrera F. Endometriosis. A life-long journey (Article in Spanish). Cl\u00ednica Investig Ginecol Obstet. 2021, 48:100686. 10.1016\/j.gine.2021.100686","journal-title":"Cl\u00ednica Investig Ginecol Obstet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.745548","article-title":"Pathogenesis based diagnosis and treatment of endometriosis","volume":"12","author":"Koninckx PR","year":"2021","unstructured":"Koninckx PR, Fernandes R, Ussia A, et al.. Pathogenesis based diagnosis and treatment of endometriosis. Front Endocrinol (Lausanne). 2021, 12:745548. 10.3389\/fendo.2021.745548","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111342","article-title":"GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis?","volume":"22","author":"Donnez J","year":"2021","unstructured":"Donnez J, Dolmans MM. GnRH antagonists with or without add-back therapy: a new alternative in the management of endometriosis?. Int J Mol Sci. 2021, 22:11342. 10.3390\/ijms222111342","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38136","article-title":"Gonadotropin-releasing hormone (GnRH)\/GnRH receptors and their role in the treatment of endometriosis","volume":"15","author":"Resta C","year":"2023","unstructured":"Resta C, Moustogiannis A, Chatzinikita E, et al.. Gonadotropin-releasing hormone (GnRH)\/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023, 15:e38136. 10.7759\/cureus.38136","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S442357","article-title":"Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: a review of evidence of a novel class of hormonal agents","volume":"16","author":"Othman ER","year":"2024","unstructured":"Othman ER, Al-Hendy A, Mostafa R, Lambalk CB, Mijatovic V. Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: a review of evidence of a novel class of hormonal agents. Int J Womens Health. 2024, 16:309-21. 10.2147\/IJWH.S442357","journal-title":"Int J Womens Health"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02018-3","article-title":"Relugolix\/estradiol\/norethisterone acetate: a review in endometriosis-associated pain","volume":"84","author":"Blair HA","year":"2024","unstructured":"Blair HA. Relugolix\/estradiol\/norethisterone acetate: a review in endometriosis-associated pain. Drugs. 2024, 84:449-57. 10.1007\/s40265-024-02018-3","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","article-title":"Scales and lists for evaluating the quality of scientific studies (Article in Spanish)","volume":"24","author":"da Silva FC","year":"2013","unstructured":"da Silva FC, Arancibia BA, da Rosa Iop R, Gutierres Filho PJ, da Silva R. Scales and lists for evaluating the quality of scientific studies (Article in Spanish). Rev Cuba Inf Cienc Salud. 2013, 24:295-312.","journal-title":"Rev Cuba Inf Cienc Salud"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ciresp.2013.08.002","article-title":"[GRADE system: classification of quality of evidence and strength of recommendation] (Article in Spanish)","volume":"92","author":"Aguayo-Albasini JL","year":"2014","unstructured":"Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. [GRADE system: classification of quality of evidence and strength of recommendation] (Article in Spanish). Cir Esp. 2014, 92:82-8. 10.1016\/j.ciresp.2013.08.002","journal-title":"Cir Esp"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693057","article-title":"Quality of Life Assessment by the Endometriosis Health Profile (EHP-30) Questionnaire prior to treatment for ovarian endometriosis in Brazilian women","volume":"41","author":"Florentino AV","year":"2019","unstructured":"Florentino AV, Pereira AM, Martins JA, Lopes RG, Arruda RM. Quality of Life Assessment by the Endometriosis Health Profile (EHP-30) Questionnaire prior to treatment for ovarian endometriosis in Brazilian women. Rev Bras Ginecol Obstet. 2019, 41:548-54. 10.1055\/s-0039-1693057","journal-title":"Rev Bras Ginecol Obstet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052664","article-title":"Uterine Fibroid Symptom and Quality of Life questionnaire (UFS-QOL NL) in the Dutch population: a validation study","volume":"11","author":"Keizer AL","year":"2021","unstructured":"Keizer AL, van Kesteren PJ, Terwee C, de Lange ME, Hehenkamp WJ, Kok HS. Uterine Fibroid Symptom and Quality of Life questionnaire (UFS-QOL NL) in the Dutch population: a validation study. BMJ Open. 2021, 11:e052664. 10.1136\/bmjopen-2021-052664","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-17-00088","article-title":"Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults","volume":"2","author":"Delgado DA","year":"2018","unstructured":"Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J Am Acad Orthop Surg Glob Res Rev. 2018, 2:e088. 10.5435\/JAAOSGlobal-D-17-00088","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"ref24","unstructured":"Numeric rating scale (NRS). (2025). Accessed. July 5, 2025: https:\/\/www.painscale.com\/article\/numeric-rating-scale-nrs."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/1933719114549848","article-title":"Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density","volume":"21","author":"Carr B","year":"2014","unstructured":"Carr B, Dmowski WP, O'Brien C, et al.. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014, 21:1341-51. 10.1177\/1933719114549848","journal-title":"Reprod Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor HS","year":"2017","unstructured":"Taylor HS, Giudice LC, Lessey BA, et al.. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017, 377:28-40. 10.1056\/NEJMoa1700089","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey E","year":"2018","unstructured":"Surrey E, Taylor HS, Giudice L, et al.. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018, 132:147-60. 10.1097\/AOG.0000000000002675","journal-title":"Obstet Gynecol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.07.055","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study","volume":"115","author":"Osuga Y","year":"2021","unstructured":"Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021, 115:397-405. 10.1016\/j.fertnstert.2020.07.055","journal-title":"Fertil Steril"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2021.11.013","article-title":"Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study","volume":"117","author":"Harada T","year":"2022","unstructured":"Harada T, Osuga Y, Suzuki Y, Fujisawa M, Fukui M, Kitawaki J. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022, 117:583-92. 10.1016\/j.fertnstert.2021.11.013","journal-title":"Fertil Steril"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00622-5","article-title":"Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)","volume":"399","author":"Giudice LC","year":"2022","unstructured":"Giudice LC, As-Sanie S, Ferreira JC, et al.. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet. 2022, 399:2267-79. 10.1016\/S0140-6736(22)00622-5","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2024.06.009","article-title":"Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain","volume":"122","author":"As-Sanie S","year":"2024","unstructured":"As-Sanie S, Abrao MS, Reznichenko G, et al.. Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain. Fertil Steril. 2024, 122:687-95. 10.1016\/j.fertnstert.2024.06.009","journal-title":"Fertil Steril"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001842","article-title":"Efficacy and safety of oral gonadotropin-releasing hormone antagonist, relugolix, in endometriosis: a meta-analysis of randomized clinical trials","volume":"32","author":"Sobral MV","year":"2025","unstructured":"Sobral MV, Dos Santos JP, Vilela TA, Pirolla RD, Barreiros FA, de Moraes MA. Efficacy and safety of oral gonadotropin-releasing hormone antagonist, relugolix, in endometriosis: a meta-analysis of randomized clinical trials. Am J Ther. 2025, 32:e309-12. 10.1097\/MJT.0000000000001842","journal-title":"Am J Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-15-0113","article-title":"60 years of neuroendocrinology: the hypothalamo-pituitary-gonadal axis","volume":"226","author":"Plant TM","year":"2015","unstructured":"Plant TM. 60 years of neuroendocrinology: the hypothalamo-pituitary-gonadal axis. J Endocrinol. 2015, 226:T41-54. 10.1530\/JOE-15-0113","journal-title":"J Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06862-0","article-title":"Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis","volume":"308","author":"Xin L","year":"2023","unstructured":"Xin L, Ma Y, Ye M, Chen L, Liu F, Hou Q. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis. Arch Gynecol Obstet. 2023, 308:1047-56. 10.1007\/s00404-022-06862-0","journal-title":"Arch Gynecol Obstet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014788.pub2","article-title":"Gonadotropin-releasing hormone analogues for endometriosis","volume":"6","author":"Veth VB","year":"2023","unstructured":"Veth VB, van de Kar MM, Duffy JM, van Wely M, Mijatovic V, Maas JW. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database Syst Rev. 2023, 6:CD014788. 10.1002\/14651858.CD014788.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmaa009","article-title":"Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure","volume":"26","author":"Reis FM","year":"2020","unstructured":"Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020, 26:565-85. 10.1093\/humupd\/dmaa009","journal-title":"Hum Reprod Update"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.10.022","article-title":"Estrogen-progestins and progestins for the management of endometriosis","volume":"106","author":"Vercellini P","year":"2016","unstructured":"Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016, 106:1552-71.e2. 10.1016\/j.fertnstert.2016.10.022","journal-title":"Fertil Steril"},{"key":"ref38","article-title":"Bone mineral density in postmenopausal women treated with 17 \u03b2-estradiol\/ drospirenone (Article in Spanish)","volume":"4","author":"Baabel-Romero N","year":"2022","unstructured":"Baabel-Romero N, Urdaneta JR, Baabel-Zambrano N, Mejia R, Levy A. Bone mineral density in postmenopausal women treated with 17 \u03b2-estradiol\/ drospirenone (Article in Spanish). Rev Estud Cienc Estud Unidad Salud. 2022, 4:15-26.","journal-title":"Rev Estud Cienc Estud Unidad Salud"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403186-efficacy-of-elagolix-and-relugolix-for-the-treatment-of-pelvic-pain-in-patients-with-endometriosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:27:12Z","timestamp":1757690832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403186-efficacy-of-elagolix-and-relugolix-for-the-treatment-of-pelvic-pain-in-patients-with-endometriosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.92149","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}